Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando Magro

Showing results (271-280 of 340) with videos related to

Pageof 34
Sort By:
Journal of Crohn'S & Colitis|February 4, 2017
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch DisordersFernando Magro, Paolo Gionchetti, Rami Eliakim, et al.
Medrxiv : the Preprint Server for Health Sciences|February 27, 2026
Integrated metabolomics and genetic analyses reveal loss of protective docosahexaenoic acid as a key driver linking ultra-processed food to Crohn's disease riskSidan Wang, Lintao Dan, Xixian Ruan, et al.
Alimentary Pharmacology & Therapeutics|April 2, 2019
Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patientsLieven Pouillon, Silvio Danese, Ailsa Hart, et al.
United European Gastroenterology Journal|October 13, 2025
Disease Monitoring in Inflammatory Bowel Disease Daily Clinical Practice and Impact on Treatment Decision Making: Real World Evidence From the Inflammatory Bowel Disease-PODCAST StudyAxel Dignass, Fernando Magro, Ferdinando D'Amico, et al.
Inflammatory Bowel Diseases|February 25, 2009
Crohn's disease in a southern European country: Montreal classification and clinical activityFernando Magro, Francisco Portela, Paula Lago, et al.
Journal of Crohn'S & Colitis|May 20, 2026
Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensusPauline Wils, Vipul Jairath, Bruce E Sands, et al.
Therapeutic Advances in Gastroenterology|September 14, 2019
Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumabFernando Magro, Susana Lopes, Marco Silva, et al.
Virchows Archiv : an International Journal of Pathology|February 4, 2014
The histopathological approach to inflammatory bowel disease: a practice guideCord Langner, Fernando Magro, Ann Driessen, et al.
The American Journal of Gastroenterology|May 1, 2026
Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension StudyGary R Lichtenstein, Jessica R Allegretti, David T Rubin, et al.
Journal of Crohn'S & Colitis|May 27, 2016
Histological Outcomes and Predictive Value of Faecal Markers in Moderately to Severely Active Ulcerative Colitis Patients Receiving InfliximabFernando Magro, Susana Isabel Lopes, Joanne Lopes, et al.
Pageof 34

Showing results (271-280 of 340) with videos related to

Sort By:
Pageof 34
Journal of Crohn'S & Colitis|February 4, 2017
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch DisordersFernando Magro, Paolo Gionchetti, Rami Eliakim, et al.
Medrxiv : the Preprint Server for Health Sciences|February 27, 2026
Integrated metabolomics and genetic analyses reveal loss of protective docosahexaenoic acid as a key driver linking ultra-processed food to Crohn's disease riskSidan Wang, Lintao Dan, Xixian Ruan, et al.
Alimentary Pharmacology & Therapeutics|April 2, 2019
Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patientsLieven Pouillon, Silvio Danese, Ailsa Hart, et al.
United European Gastroenterology Journal|October 13, 2025
Disease Monitoring in Inflammatory Bowel Disease Daily Clinical Practice and Impact on Treatment Decision Making: Real World Evidence From the Inflammatory Bowel Disease-PODCAST StudyAxel Dignass, Fernando Magro, Ferdinando D'Amico, et al.
Inflammatory Bowel Diseases|February 25, 2009
Crohn's disease in a southern European country: Montreal classification and clinical activityFernando Magro, Francisco Portela, Paula Lago, et al.
Journal of Crohn'S & Colitis|May 20, 2026
Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensusPauline Wils, Vipul Jairath, Bruce E Sands, et al.
Therapeutic Advances in Gastroenterology|September 14, 2019
Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumabFernando Magro, Susana Lopes, Marco Silva, et al.
Virchows Archiv : an International Journal of Pathology|February 4, 2014
The histopathological approach to inflammatory bowel disease: a practice guideCord Langner, Fernando Magro, Ann Driessen, et al.
The American Journal of Gastroenterology|May 1, 2026
Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension StudyGary R Lichtenstein, Jessica R Allegretti, David T Rubin, et al.
Journal of Crohn'S & Colitis|May 27, 2016
Histological Outcomes and Predictive Value of Faecal Markers in Moderately to Severely Active Ulcerative Colitis Patients Receiving InfliximabFernando Magro, Susana Isabel Lopes, Joanne Lopes, et al.
Pageof 34